Day One

Wednesday 17th April 2024

8:00 am Check In, Morning Coffee & Light Breakfast

8:55 am Chair’s Opening Remarks

Uncovering New Targetable Pathways in Inflammatory-Mediated Disease: Forming the Basis for Developing Safe & Effective Therapies

9:00 am Unraveling New Mechanisms in Itch from Targeting Type 2 Inflammation

Synopsis

  • Understanding shared and unique characteristics of AD, PN and CSU
  • How type 2 inflammation contributes to neuroimmune dysregulation 
  • Potential for IL-4Ra antagonism to reduce itch in chronic inflammatory skin diseases.

9:30 am Topical Biologics for the Treatment of Inflammatory Disorders Including Pruritus, AD, & Acne

Synopsis

• Discussion of the drug development evolution of a first-in-class therapy

• Results from previous Phase 2 studies

• Roadmapping what is next to bring these novel therapeutics to market

10:00 am Morning Break & Speed Networking

Synopsis

Meet and connect with your peers in this dedicated networking session

11:00 am Elevating Dermatological Drug Development Through Advanced Inflammatory Marker Targeting Methodology

  • Tamar Ben Yedidia CSO and clinical management, Scinai Immunotherapeutics
  • Michael Schön Professor and Chairman, Department of Dermatology, Venereology & Allergology, University Medical Center Goettingen

Synopsis

• Speaking to preclinical study design to evaluate anti-interleukin 17 NanoAbs as a treatment for plaque psoriasis, which showed the downregulation of psoriasis molecular markers

• Leveraging 3D biologic skin models to mimic the structure of human skin to suggest NanoAbs’ therapeutic potential

• Demonstrating the potential for a systemic novel approach with higher affinity for IL-17F isoform to improve treatment efficacy for patients with psoriasis

Biomarkers in Dermatology: Building Better Patient Population Insights Into Drug Development Strategy Planning

11:30 am Biomarker-Driven Drug Development in Dermatology

Synopsis

• How leveraging and integrating methodologies, including RNA sequencing and multiomics approaches can verify drug pharmacodynamics, demonstrating efficacy and safety through biomarkers

• Investigator-initiated studies with approved drugs to validate novel endpoints

• Deep-phenotyping of patients with inflammatory skin diseases for stratification and improved disease understanding

• Case study with anti-IL-23 therapy for psoriasis, presenting recent outcomes using a technology driven approach

12:00 pm Lunch Break

Synopsis

Take this chance to meet the expert speakers, connect with your peers and explore our exhibition hall to meet fresh and familiar faces or even your next partner!

1:00 pm Disease Modification in Dermatology: A Novel, First in Class Targeted Therapy for the Non-Immunosuppressive Treatment of Pemphigus & Stevens-Johnson/Toxic Epidermal Necrolysis syndrome

Synopsis

  • Development of a human monoclonal antibody against Fas ligand (PC111) that plays a major role in the pathogenesis of pemphigus and Stevens-Johnson/Toxic Epidermal Necrolysis syndrome
  • Sharing recent data demonstrating targeted therapy, that acts downstream of the immune system, highly differentiates from currently used potent immunosuppressors, with a good safety profile, meeting patients’ satisfaction
  • PC111 will be the first targeted therapy for Stevens-Johnson/Toxic Epidermal Necrolysis syndrome, acute and deadly diseases for which no approved drug exists

1:30 pm AI Assisted Objective Skin Imaging & Analysis of Skin Diseases & Drug Effects in Clinical Trials

Synopsis

• Standardised high quality mobile skin imaging

• Smart skin imaging data and objective image analysis

Machine learning and AI powered decision support in Psoriasis, Hidradenitis and more disease areas

New digital skin biomarker and endpoints in clinical R&D and post marketing 

2:00 pm Afternoon Networking Break

Optimising Drug Delivery to Target Sites with Improved Stability & Bioavailability

2:45 pm Panel Session : Route of Administration & Formulations: How Can We Improve?

Synopsis

Delving into the complexities of selecting appropriate routes of administration and formulation strategies, learn expert takes on:

• How can biopharma better formulate drugs to effectively bypass or overcome the skin’s barrier function?

• What’s needed, from a drug delivery system perspective, to ensure optimal therapeutic outcomes and reduce potential side efects?

• What do biopharma developing therapeutics for immune-mediated dermatological conditions in dermatology need to consider in relation to drug route of administration across small molecule, biologic and mAb therapies?

• How can industry improve to accelerate the development of orally administered drugs?

3:30 pm Detailing Hedgehog-Signalling Inhibition as a Promising Target for Unmet Needs in the Dermatology Universe

  • Ofer Toledano Vice President - Research & Development, Sol Gel Technologies

Synopsis

• Exploring the mechanism of Patidegib a hedgehog inhibitor (HHI) blocker, preventing new basal cell carcinomas in Gorlin Syndrome

• Current data showcasing the potential of this mechanism and highlighting the benefits of topical HHIs over oral HHIs

Beyond Dermatology: Realising Opportunities for Disease with Inflammatory Components

4:00 pm Panel Session : Unlocking Synergies: Extending Dermatological Drug Development Insights to Address Broader Inflammatory Diseases

Synopsis

Gain insights into the extension of knowledge from immuno-dermatological drug development to encompass a broader range of inflammatory diseases, including Rheumatoid Arthritis, Systemic Lupus Erythematosus, Inflammatory Bowel Disease and more:

• How can advancements in our mechanistic understanding of dermatological drug development interactions targeting inflammatory pathways be leveraged to benefit patients with other inflammatory diseases?

• What are the key challenges in translating dermatological drug discoveries into therapies for broader inflammatory conditions, such as rheumatoid arthritis or inflammatory bowel disease?

• How can we ensure that cross-pollination efforts align with the diverse needs and experiences of patients with various inflammatory conditions?

• What strategies and initiatives can facilitate greater collaboration and knowledge sharing in the field of dermatology and broader inflammatory diseases?

• How can these advancements in precision medicine and biomarker development in dermatology be extended to identify patient populations in other inflammatory diseases who are most likely to benefit from cross-pollinated therapies, ensuring more targeted treatment approaches?

Moderated by: Nidhi Malhotra, Principal Scientist, MSD

4:45 pm Chair’s Closing Remarks & End of Day One